Trends in Clinical Development for PD-1/PD-L1 Inhibitors
Article reprint from Nature Reviews Drug Discovery
Article
Apr 17, 2020

This March 2020 article in Nature Reviews Drug Discovery outlines trends in the current landscape of clinical trials evaluating PD-1/PD-L1-targeted monoclonal antibodies, which are now the standard of care for 16 different types of cancer and tissue-agnostic indications. IQVIA and Cancer Research Institute collaborated on the analyses and report.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.